World Journal of Cardiology最新文献_第2页

Evaluating inflammatory status to predict atrial fibrillation recurrence following ablation: The role of systemic immune-inflammation index.

IF 1.9

World Journal of Cardiology Pub Date : 2025-03-26 DOI: 10.4330/wjc.v17.i3.103074

Amedeo Tirandi, Federico Carbone, Luca Liberale, Fabrizio Montecucco

{"title":"Evaluating inflammatory status to predict atrial fibrillation recurrence following ablation: The role of systemic immune-inflammation index.","authors":"Amedeo Tirandi, Federico Carbone, Luca Liberale, Fabrizio Montecucco","doi":"10.4330/wjc.v17.i3.103074","DOIUrl":"10.4330/wjc.v17.i3.103074","url":null,"abstract":"Atrial fibrillation (AF) is the most common arrhythmia in humans, affecting more than 40 million people worldwide. Radiofrequency catheter ablation (RFCA) was first introduced as a treatment for AF by Haïssaguerre M in the late 1990s. This procedure quickly became the treatment of choice, especially for symptomatic patients with AF refractory to medication. However, up to 45% of patients may experience AF recurrence within 12 months after RFCA. In this setting, AF recurrence is likely multifactorial, including atrial remodeling, local fibrosis or incomplete ablation due to failure in locating the trigger. Additionally, patients with obesity, sleep apnea, hypertension, or diabetes are at an increased risk of AF recurrence after RFCA. Inflammation is increasingly recognized as a potential key factor in AF recurrence and may arise both from the healing response of heart tissue post-ablation or from chronic low-grade inflammation, as observed in many risk factors. Here, we present an original study by Wang et al, which investigated the combination of the systemic immune-inflammation index-a marker developed to assess overall inflammatory status-and the APPLE score, designed to predict AF recurrence following RFCA. The study found that using both indicators together improved the accuracy of AF recurrence prediction. These findings underscore the significant role of inflammation in cardiovascular disease and demonstrated its impact on AF recurrence after RFCA. Further research is warranted to validate the combined use of these two scores in clinical settings for predicting AF recurrence following catheter ablation.","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 3","pages":"103074"},"PeriodicalIF":1.9,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification and management of esophageal and pericardial perforations: A case report.

IF 1.9

World Journal of Cardiology Pub Date : 2025-03-26 DOI: 10.4330/wjc.v17.i3.102104

Nan Ma, Zhong-Wei Li

引用次数: 0

Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.103845

Li-You Lian, Chen-Xiao Huang, Qin-Fen Chen, Xiao-Dong Zhou

引用次数: 0

Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.103950

Nan Tang, Kang-Ming Li, Hao-Ran Li, Qing-Dui Zhang, Ji Hao, Chun-Mei Qi

{"title":"Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.","authors":"Nan Tang, Kang-Ming Li, Hao-Ran Li, Qing-Dui Zhang, Ji Hao, Chun-Mei Qi","doi":"10.4330/wjc.v17.i2.103950","DOIUrl":"10.4330/wjc.v17.i2.103950","url":null,"abstract":"Percutaneous coronary intervention (PCI), as an essential treatment for coronary artery disease, has significantly improved the prognosis of patients with large coronary artery lesions. However, some patients continue to experience myocardial ischemic symptoms post-procedure, largely due to coronary microvascular dysfunction (CMD). The pathophysiological mechanisms of CMD are complex and involve endothelial dysfunction, microvascular remodeling, reperfusion injury, and metabolic abnormalities. Moreover, components of metabolic syndrome, including obesity, hyperglycemia, hypertension, and dyslipidemia, exacerbate the occurrence and progression of CMD through multiple pathways. This review systematically summarizes the latest research advancements in CMD after PCI, including its pathogenesis, diagnostic techniques, management strategies, and future research directions. For diagnosis, invasive techniques such as coronary flow reserve and the index of microcirculatory resistance, as well as non-invasive imaging modalities (positron emission tomography and cardiac magnetic resonance), provide tools for early CMD detection. In terms of management, a multi-level intervention strategy is emphasized, incorporating lifestyle modifications (diet, exercise, and weight control), pharmacotherapy (vasodilators, hypoglycemic agents, statins, and metabolic modulators), traditional Chinese medicine, and specialized treatments (enhanced external counterpulsation, metabolic surgery, and lipoprotein apheresis). However, challenges remain in CMD treatment, including limitations in diagnostic tools and the lack of personalized treatment strategies. Future research should focus on the complex interactions between CMD and metabolic risks, aiming to optimize diagnostic and therapeutic strategies to improve the long-term prognosis of patients post-PCI.","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 2","pages":"103950"},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Large left atrial myxoma with synchronous laryngeal squamous cell carcinoma: A case report.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.100952

Ling Zhu, Jax Yuan-Zhe Neo, Lavisha S Punjabi, Siang-Hui Lai, Yeow-Leng Chua

{"title":"Large left atrial myxoma with synchronous laryngeal squamous cell carcinoma: A case report.","authors":"Ling Zhu, Jax Yuan-Zhe Neo, Lavisha S Punjabi, Siang-Hui Lai, Yeow-Leng Chua","doi":"10.4330/wjc.v17.i2.100952","DOIUrl":"10.4330/wjc.v17.i2.100952","url":null,"abstract":"Background: Cardiac myxoma is a benign neoplasm and one of the most common types of primary cardiac tumors. Synchronous cardiac myxoma and other malignancies are extremely rare, and only limited cases have been reported.Case summary: We describe a young patient with newly diagnosed locally advanced laryngeal cancer, with a synchronous cardiac tumor detected on staging scans. An echocardiogram showed the typical appearance of myxoma in the left atrium. Early cardiac surgery was performed in view of its obstructive features and post cardiac surgery recovery was uneventful. The patient was scheduled for subsequent oncological treatment for the laryngeal cancer. However, due to rapid progression of the advanced laryngeal malignancy, he was placed on supportive care.Conclusion: To our knowledge, this is the first reported case of synchronous cardiac myxoma with laryngeal malignancy. Individualized treatment strategy should be adopted to manage synchronous tumors in a multidisciplinary approach. The most life-threatening condition needs be treated first. Single resection, staged operations or simultaneous resection of both tumors have been reported with good outcomes.","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 2","pages":"100952"},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From surgery to recovery: Measuring success through quality of life and functional improvements after cardiac surgery.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.100213

Peng Li, Hui-Ping Zhang

引用次数: 0

Risk stratification for future cardiac arrest after COVID-19 vaccination.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.103909

Peter A McCullough, Nicolas Hulscher

{"title":"Risk stratification for future cardiac arrest after COVID-19 vaccination.","authors":"Peter A McCullough, Nicolas Hulscher","doi":"10.4330/wjc.v17.i2.103909","DOIUrl":"10.4330/wjc.v17.i2.103909","url":null,"abstract":"Unheralded cardiac arrest among previously healthy young people without antecedent illness, months or years after coronavirus disease 2019 (COVID-19) vaccination, highlights the urgent need for risk stratification. The most likely underlying pathophysiology is subclinical myopericarditis and reentrant ventricular tachycardia or spontaneous ventricular fibrillation that is commonly precipitated after a surge in catecholamines during exercise or the waking hours of terminal sleep. Small patches of inflammation and/or edema can be missed on cardiac imaging and autopsy, and the heart can appear grossly normal. This paper reviews evidence linking COVID-19 vaccines to cardiac arrest where unfortunately the majority of victims have had no antecedent clinical evaluation. We propose a comprehensive strategy for evaluating cardiovascular risk post-vaccination, incorporating detailed patient history, antibody testing, and cardiac diagnostics in the best attempt to detect abnormalities before sudden cardiac death. This approach aims to identify individuals at higher risk of cardiac events after COVID-19 vaccination and guide appropriate clinical management. It is prudent for each primary care physician to have a pre-established plan when addressing this issue in their practice.","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 2","pages":"103909"},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in breathomics behavior in ischemic heart disease and heart failure, mass-spectrometry.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.102851

Basheer Abdualah Marzoog, Peter Chomakhidze, Daria Gognieva, Alena Yurievna Parunova, Snezhana Nikolaevna Demchuk, Artemiy Silantyev, Natalia Kuznetsova, Anastasia Kostikova, Dmitrii Podgalo, Evgeny Nagornov, Aida Gadzhiakhmedova, Philipp Kopylov

{"title":"Updates in breathomics behavior in ischemic heart disease and heart failure, mass-spectrometry.","authors":"Basheer Abdualah Marzoog, Peter Chomakhidze, Daria Gognieva, Alena Yurievna Parunova, Snezhana Nikolaevna Demchuk, Artemiy Silantyev, Natalia Kuznetsova, Anastasia Kostikova, Dmitrii Podgalo, Evgeny Nagornov, Aida Gadzhiakhmedova, Philipp Kopylov","doi":"10.4330/wjc.v17.i2.102851","DOIUrl":"10.4330/wjc.v17.i2.102851","url":null,"abstract":"Background: Cardiovascular disease (CVD) and associated sequalae remain the leading cause of disability worldwide. Ischemic heart disease (IHD) and heart failure are the most common etiologies of morbidity and mortality worldwide. This is due to the poor diagnostic and management methods for heart failure and IHD. Early detection of related risk factors through modern strategies is underestimated and requires further research.Aim: To interpret data from the published literature on volatile organic compounds (VOC), including all the methods used to analyze exhaled breath in patients with IHD and heart failure.Methods: Searches for specific keywords were performed on Scopus and PubMed. A total of 20 studies were identified in breath analysis and IHD and heart failure. The study is registered in PROSPERO (Registration No. CRD42023470556).Results: Considering the articles found, more research is required to gain a full understanding of the role of VOCs in IHD and heart failure. However, the existing literature demonstrates that cardiac metabolic changes can be expressed in exhaled air. The number of papers found is extremely low, making interpretation extremely difficult.Conclusion: Exhaled breath analysis can be a novel biomarker for the diagnosis and prevention of heart failure and IHD. Exhaled breath analysis can be used as a mirror to reflect the metabolic changes related to IHD and heart failure.","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 2","pages":"102851"},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging roles of the acid sphingomyelinase/ceramide pathway in metabolic and cardiovascular diseases: Mechanistic insights and therapeutic implications.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.102308

Hong-Ni Wang, Ye Wang, Si-Yao Zhang, Lan Bai

{"title":"Emerging roles of the acid sphingomyelinase/ceramide pathway in metabolic and cardiovascular diseases: Mechanistic insights and therapeutic implications.","authors":"Hong-Ni Wang, Ye Wang, Si-Yao Zhang, Lan Bai","doi":"10.4330/wjc.v17.i2.102308","DOIUrl":"10.4330/wjc.v17.i2.102308","url":null,"abstract":"Metabolic diseases have emerged as a leading cause of mortality from non-communicable diseases, posing a significant global public health challenge. Although the association between ceramides (Cers) and metabolic diseases is well-established, the role of the acid sphingomyelinase (ASMase)/Cer pathway in these diseases remains underexplored. This review synthesizes recent research on the biological functions, regulatory mechanisms, and targeted therapies related to the ASMase/Cer pathway in metabolic conditions, including obesity, diabetes, non-alcoholic fatty liver disease, and cardiovascular disease. The effects of the ASMase/Cer pathway on metabolic disease-related indicators, such as glycolipid metabolism, insulin resistance, inflammation, and mitochondrial homeostasis are elucidated. Moreover, this article discusses the therapeutic strategies using ASMase/Cer inhibitors for inverse prevention and treatment of these metabolic diseases in light of the possible efficacy of blockade of the ASMase/Cer pathway in arresting the progression of metabolic diseases. These insights offered herein should provide insight into the contribution of the ASMase/Cer pathway to metabolic diseases and offer tools to develop therapeutic interventions for such pathologies and their severe complications.","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 2","pages":"102308"},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Left bundle branch pacing cardiac resynchronization therapy vs biventricular pacing cardiac resynchronization therapy-time to write a requiem for biventricular pacing-cardiac resynchronization therapy.

IF 1.9

World Journal of Cardiology Pub Date : 2025-02-26 DOI: 10.4330/wjc.v17.i2.103356

Akshyaya Pradhan, Daljeet Saggu, Monika Bhandari

{"title":"Left bundle branch pacing cardiac resynchronization therapy vs biventricular pacing cardiac resynchronization therapy-time to write a requiem for biventricular pacing-cardiac resynchronization therapy.","authors":"Akshyaya Pradhan, Daljeet Saggu, Monika Bhandari","doi":"10.4330/wjc.v17.i2.103356","DOIUrl":"10.4330/wjc.v17.i2.103356","url":null,"abstract":"Cardiac resynchronization therapy (CRT) reduces heart failure (HF) hospitalizations and all-cause mortality in patients with HF with reduced ejection fraction with left bundle branch (LBB) block. Biventricular pacing (BVP) is considered the gold standard for achieving CRT; however, approximately 30%-40% of patients do not respond to BVP-CRT. Recent studies have demonstrated that LBB pacing (LBBP) produces remarkable results in CRT. In this meta-analysis, LBBP-CRT showed better outcomes than conventional BVP-CRT, including greater QRS duration reduction and left ventricular ejection fraction improvement, along with consistently lower pacing thresholds on follow-up. Additionally, there was a greater reduction in New York Heart Association class and brain natriuretic peptide levels. This study contributes to the growing body of encouraging data on LBBP-CRT from recent years. With ongoing technological advancements and increasing operator expertise, the day may not be far when LBBP-CRT becomes the standard of care rather than the exception.","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"17 2","pages":"103356"},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0